Mcallen, TX – According to filings with the U.S. Securities and Exchange Commission, Hera Diagnostics is raising $3,660,382.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Teofilo Tijerina played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hera Diagnostics
Hera Medical Devices uses optical and electrical spectroscopy, along with sophisticated artificial intelligence algorithms to detect cancer lesions in cells. Our first product is InstaPap, a cervical cancer screening device used at the point of care with immediate results and a much more comfortable patient experience. Subsequent development will be in the areas of skin, throat, and stomach cancer.

To learn more about Hera Diagnostics, visit http://www.hera-diagnostics.com/

Contact:
Teofilo Tijerina, Chief Executive Officer
281-794-9800

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved